Objective
to report the final 5-year clinical outcomes of PCI with FIREHAWK biodegradable polymer sirolimus-eluting stent (BP-SES) as compared to durable polymer everolimus-eluting stent Xience (DP-EES)
Study
multicentre open-label non-inferiority randomised trial
Population
all-comers
Endpoints
target lesion failure (TLF) as composite of cardiac death, MI or ischaemia-driven target lesion revascularisation at 5 years
Conclusion
PCI in all-comers using BP-SES compared to DP-EES was non-inferior during 5 years follow-up